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Thyroid cancer is the endocrine tumor that bears the highest incidence with 33550 new cases per year. It bears an excellent
prognosis with a mortality of 1530 patients per year (Jemal et al.; 2007). We have been treating patients with thyroid carcinoma
during many years without many innovations. Recently, we have assisted to the development of new agents for the treatment of
this disease with unexpected good results. Here we present a review with the old and new methods for the treatment of this disease.
1.Introduction
Thyroid carcinoma usually presents as a palpable thyroid
nodule or a nodule that is discovered incidentally on neck
imaging for evaluation because of another reason. Less
c o m m o n l yi tm a yp r e s e n ta sal a t e r a ln e c km a s s[ 1]. The rate
of malignancy for a thyroid nodule is of only 4-5% [2, 3].
The prevalence of thyroid nodules increases with age and is
estimated to occur in roughly 50% of the US population 50
years of age and older [4] .T h y r o i dc a n c e rm a yp r e s e n ta sa
dominant nodule in a multinodular gland or as a solitary
nodule. The risk per gland is equivalent in multinodular
and in solitary nodule [5]. Incidentally discovered nodules
carry a similar risk of malignancy [6]. Every nodule should
be evaluated. Upon initial presentation, a careful history is
essential because it can reveal information that immediately
stratiﬁes a patient into a high risk category. High risk factors
include a prior history of head and neck radiation including
radiation for Hodgkin’s disease [7], radiation exposure from
the Chernobyl accident [8] and a family history of thyroid
cancer. The risk of thyroid cancer in ﬁrst degree relatives of
patients with diﬀerentiated thyroid cancer has been shown
to be six times that of the general population [9]. Other
important high risk factors include a history of rapid growth
of a solid nodule, pain, dysphagia, or dysphonia. Although
lessthan20%ofpatientswiththyroidcarcinomawillpresent
with a regional metastasis, a neck mass in the presence of
a thyroid nodule raises the likelihood of malignancy. Young
age (<20 years), older age (>70 years), and male gender may
also represent an increased risk [10]. To most accurately
determine the risk of malignancy, it is essential to consider
a variety of factors (Table 1). There is no single laboratory
study that is able to determine the presence of thyroid
malignancy. Although elevated baseline calcitonin levels
represent occult medullary carcinoma in 10–40% of cases,
the presence of false positive elevations, the low incidence of2 Journal of Thyroid Research
Table 1: Risk factors for thyroid carcinoma.
History of radiation exposure
Family history of papillary thyroid carcinoma
Single dominant solid nodule greater than 4cm
Male gender
Rapid growth of a nodule
Younger than 20 years old
Older than 70 years old
Cervical metastasis
Evidence of invasion on imaging
medullary carcinoma, and the high cost of testing have led
to recommendations against routine testing in the United
States [11]. Calcitonin levels are usually reserved for high
risk patients and those with a family history of medullary
thyroid carcinoma or multiple endocrine neoplasia (MEN).
Thyroglobulin is not useful in the work up because there
are a variety of conditions that can lead to elevated levels
including thyroid inﬂammation, glandular stimulation or
injury following radiation, surgery, or even a biopsy. TSH
should be measured to exclude a toxic nodule, as toxic
nodules are almost never malignant and generally do not
require ﬁne needle aspiration. If the TSH is suppressed, then
radioisotope imaging should be performed to conﬁrm and
localize the toxic nodule(s).
1.1. Clinical Staging and Risk Group Classiﬁcation. Clinical
stagingandriskgroupclassiﬁcationisparticularlyimportant
in the management of thyroid cancer because it often will
direct management, in particular the decision to treat the
patient with radioactive iodine, external beam radiation, or
combination therapy. The lack of prospective randomized
studies assessing the relationships between tumor stage,
treatment, and outcome, means that the majority of data
that is used to create risk-group classiﬁcations is derived
from retrospective reviews. As a result, there are variety of
classiﬁcation systems that are based on factors such as age,
tumor size, gender, tumor grade, multicentricity, metastatic
disease, and other variables. The AGES system [12]i sb a s e d
on factors including age, grade, extent, and size of the
tumor (Table 2). In the AGES system, those patients with
an aggregate score 4+ are high risk and those with a score
less than 4 are low risk. The AMES system [13]c o n s i d e r s
age, distant metastasis, extent, and size of tumor (Table 3).
Additionally, there are systems devised by the European
Organization for Research on Treatment of Cancer (EORTC)
[14], the National Thyroid Cancer Treatment Cooperative
Study [15], and others [13, 16]. Most of these classiﬁcation
systems utilize similar information with minor variations.
Irrespective of the classiﬁcation system that is used, it is
important to consider risk group stratiﬁcation during the
management of a patient with thyroid cancer. Separate from
these stratiﬁcation systems is the TNM tumor staging system
(Table 4) which serves to provide a uniform language when
evaluating management and outcome.
Table 2: AGES classiﬁcation system.
Prognostic score = 0.05 × age (if age !40)
+1 (if grade 2)
+3 (if grade 3 or 4)
+1 (if extrathyroidal)
+3 (if distant spread)
+0.2 × tumor size (cm maximum diameter)
Survival by AGES score
3.99 = 99%
4–4.99 = 80%
5–5.99 = 67%
5–6 = 13%
Table 3: AMES classiﬁcation system.
Low Risk
Young patients (men “41 years old, women” 51 years old)
without distant metastasis
Older patients (intrathyroidal papillary thyroid cancer,
minor capsular invasion for follicular lesion)
Primary cancers <5cm in diameter
No distant metastasis
High Risk
All patients with distant metastasis
Extrathyroidal papillary
Major capsular invasion for follicular
All older patients with extrathyroidal spread
All older patients with primary cancer >5cm in diameter
(men > 40, women > 50)
Survival by AMES score
Low risk = 99%
High risk = 61%
2. The Old Insights
2.1. Papillary Thyroid Carcinoma. Papillary thyroid carci-
noma (PTC) is the most common form of the follicular
cell derived carcinomas and comprises three quarters of
all newly diagnosed thyroid cancers [17]. PTC is derived
from the follicular cells. These cells tend to concentrate
iodineandsecretethyroglobulin.Asaresult,surveillanceand
detectionofrecurrencecanberelativelystraightforward.The
prognosis for PTC is usually excellent.
Papillary thyroid cancers usually carry mutations and
rearrangements that activates the mitogen activated protein
kinase (MAPK). Rearrangements of RET and NTRK1 tyro-
sine kinases, activating mutations of BRAF and activating
mutations of RAS are sequential components of the MAPK
activation [18]. Papillary thyroid cancers are also connected
with rearrangements of RET and NTRK1 [19]. These rear-
rangements result in the production of chimeric proteins,
namedasRET/PTCandTRK.Anythesegenesisexpressedin
normal thyroid epithelial cells. Consequently, patients with
MEN2 syndromes do not have an increased incidence of
papillary thyroid cancer. In adults, close to 40 percent ofJournal of Thyroid Research 3
Table 4: TNM classiﬁcation system for thyroid carcinoma.
TNM Classiﬁcation System
T1 Tumor diameter 2cm or smaller
T2 Primary tumor diameter > 2t o4c m .
T3
Primary tumor diameter > 4cm limited to the thyroid or with
minimal extracapsular
extension
T4a
Tumor of any size extending beyond the thyroid capsule to
invade the subcutaneous soft
tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
T4b Tumor invades prevertebral fascia or encases carotid artery
or mediastinal nerves
Tx Primary tumor size unknown, but without extrathyroid
extension
N0 No metastatic nodes
N1a Metastasis to level VI (pretracheal, paratracheal, prelaryngeal)
NIb Metastasis to unilateral or bilateral or contralateralcervical
or superior mediastinum
Nx Nodes not assessed at surgery
M0 No distant metastasis
M1 Distant metastasis
sporadic papillary cancers have these rearrangements, with
those in RET being about three times more common [20].
The incidence of RET rearrangements in papillary cancers
is higher in children [21], aﬀecting up the 80 percent in the
case of children exposed to external x-irradiation and those
exposed to the Chernobyl nuclear accident.
2.1.1. The Case of the BRAF and RAS Mutations. The
BRAF proteins are serine-threonine kinases that activate the
RAF/MEK/MAPK signaling pathway. The T1799A mutation
oftheBRAFgene,aﬀectsupto69percentofpapillarythyroid
cancers [18, 22–24]. In one report, BRAF mutations were
found in 44 percent of 500 patients with papillary thyroid
cancer [25]. BRAF mutations may be associated with a worse
clinical prognosis [26]. BRAF mutations are associated with
extrathyroidal tissue invasion, lymph node metastases and
advanced tumor stage. Surprisingly it has been described
acquird BRAF mutations in lymph node metastases [27].
BRAF point mutations are less frequent in childhood
thyroid cancers, including those children aﬀected by the
Chernobyl nuclear calamity [28]. RAS mutations. Although
activating ras mutations are found in follicular adenomas,
they have also been reported in follicular variant of papillary
thyroid cancers [29].
There may be an increased incidence of papillary cancer
in patients with familial adenomatous polyposis [30]. The
papillarythyroidcancersofthesegrouppatientswithfamilial
adenomatous polyposis have frequent rearrangements of
RET [31].
Papillary thyroid cancers can occur as a familial syn-
drome [32]. Other family studies have indicated a familial
predisposition at 2q21 to PTC, as well as a familial predispo-
sition at 8q24 to PTC with melanoma [33].
2.1.2. Management of Papillary Thyroid Carcinoma. Surgery
is the primary treatment for papillary thyroid cancer and a
complete resection oﬀers the best chance of cure [10, 34].
While the role of a complete surgical resection is established,
the extent of the initial surgical resection has been topic
of controversy. Primary management of thyroid malignancy
has included nodulectomy, hemithyroidectomy with and
without isthmusectomy, subtotal thyroidectomy, and total
thyroidectomy. The high rate of recurrence associated with
nodulectomyhasconﬁrmedthatthisapproachisinadequate.
While there has been a trend toward more aggressive
surgical resection based on the well-documented multicen-
tric nature of the disease, there are still some who insist
that a partial thyroidectomy is suﬃcient [35] Proponents
of total thyroidectomy point to data that demonstrates a
rate of multicentric bilateral disease ranges from 18% to
46% [36, 37]. Opponents of total thyroidectomy suggest
that multicentric bilateral disease is often microscopic and
not clinically signiﬁcant. This is further supported by
the observation that several large studies have failed to
demonstrate a survival advantage to total thyroidectomy
when compared with hemithyroidectomy [38, 39]. In spite
of these ﬁndings, most clinicians agree that there is a subset
of patients who beneﬁt from total thyroidectomy while
there is another distinct subset of patients that may be
treated more conservatively. The concern regarding “over-
treating” a patient by performing a total thyroidectomy
instead of a hemithyroidectomy relates to the surgical risk
including an increased risk of vocal cord paralysis and a
risk of permanent hypoparathyroidism. In an eﬀort to guide
surgical management, the AGES and the AMES classiﬁcation
systems represent two commonly used systems that are used
to classify patients into either a “high risk” group or a “low
risk”group.Ithasbeensuggestedthat“lowrisk”patientscan
be managed with a thyroid lobectomy and isthmusectomy
while“highrisk”patientsarebettermanagedwithatotalthy-
roidectomy. Most surgeons agree with the recommendation
to perform a total thyroidectomy when faced with a high risk
patient.Howeverthecontroversyexistsinthelowriskpatient
subgroup. Several studies have failed to demonstrate that low
risk patients experience an improvement in cause-speciﬁc
mortality after undergoing a total thyroidectomy [12, 40]
while several large studies have demonstrated that there is
a beneﬁt to total thyroidectomy [39, 41]. The conﬂicting
data can make the decision-making process a diﬃcult one.
As a result, not all surgeons favor such guidelines and many
prefer to perform a total thyroidectomy in spite of the risk
stratiﬁcation suggesting that the rate of morbidity in the
hands of an experienced surgeon is exceedingly low [42].
Ar e c e n ts t u d yf o u n dt h a ts u r g e o n sw h op e r f o r mm o r e
than 100 thyroidectomies per year reported complication
rates of 4.3% while those surgeons who performed less
than 10 thyroidectomies per year reported a four-fold4 Journal of Thyroid Research
increase in complication rate. In spite of the complication
rate, when a subtotal thyroidectomy is performed for the
management of thyroid carcinoma, it becomes diﬃcult to
follow thyroglobulin levels for surveillance [43]. This may
represent the most compelling argument to perform a total
thyroidectomy for malignancy. Finally, the American Thy-
roid Association (ATA) recently recommended that a total
thyroidectomy should be performed for the management of
well-diﬀerentiated thyroid carcinoma [20].
Whereas one recent expert consensus guideline from the
ATA [4, 44], recommended consideration of routine central
neck dissection for most patients with papillary thyroid
cancer, the guideline from the National Comprehensive
Cancer Network only recommends central neck dissection in
the presence of grossly positive metastasis.
2.2. Follicular Thyroid Carcinoma. Follicular carcinoma is
less common than papillary thyroid carcinoma [17]a n d
typically behaves more aggressively than papillary thyroid
carcinoma. The aggressive nature of follicular thyroid carci-
noma is largely a result of its propensity for hematogenous
dissemination. Unlike papillary thyroid carcinoma, which
spreads through lymphatics, follicular carcinoma has a
tendency to metastasize hematogenously to the lung and
bones. The incidence of distant metastasis at presentation is
not uncommon occurring between 10 and 20% of new cases
[45–47]. As a result, a bony lesion or pathologic fracture
may represent the initial presentation. The key to eﬀective
management of follicular carcinoma is making an early
diagnosis and total thyroidectomy.
The genetics aberrations of the Follicular Thyroid can-
cer includes the translocation (t[2,3][q13;p25]) [48] that
results in fusion of part of the DNA-binding segment of
the PAX8 gene and the peroxisome proliferator-activated
receptor gamma 1 (PPAR-gamma-1) gene; PAX8 is a thyroid
transcription factor and PPAR-gamma-1 is a transcription
factor that stimulates cell diﬀerentiation and inhibits cell
growth. Its presence, may be useful to distinguish PTC from
Follicular Thyroid Cancer.
Overexpression of normal c-myc and c-fos genes, as well
as mutations of H-ras, N-ras, and K-ras protooncogenes,
is found in follicular adenomas, follicular cancers, and
occasionally papillary cancers [49, 50]. Allelic losses in these
genes, also occur frequently in follicular cancers [51].
HypermethylationofRASSF1A,aknowntumorsuppres-
sor gene, has been described in one study, in 9 of 12 follicular
thyroid cancers and in 44% of benign adenomas, and in
20% of papillary thyroid cancers reﬂecting and early step in
thyroid carcinogenesis [52].
2.2.1. Management of Follicular Thyroid Carcinoma. In
contrast to papillary thyroid cancer, the frozen section
pathologicalanalysisisnothelpfulinmakingthediagnosisof
follicular carcinoma because capsular and vascular invasion
must be identiﬁed and this requires ﬁne section analysis that
cannot be completed with FNA or at the time of frozen
section [53, 54]. The deﬁnitive diagnosis of follicular thyroid
carcinoma can be made only on permanent section. Once
the diagnosis of follicular carcinoma has been conﬁrmed,
the decision to proceed with a completion thyroidectomy or
follow the patient is based on a variety of factors including
risk group analysis. Most agree that high risk patients require
a total thyroidectomy. Not only does a total thyroidectomy
improve prognosis but it is very helpful in achieving
accurate surveillance by facilitating RAI administration and
thyroglobulin monitoring. There is controversy regarding
the low risk group patients who present with minimally
invasive lesions. The decision to perform a completion
thyroidectomy is often based on age of the patient and
invasiveness of the tumor. In patients greater than 50 years
old or those with extensive invasion, we recommend a
completion thyroidectomy.
Patientswithlowgradetumors,tumorsthatdemonstrate
minimal invasion, can be managed conservatively with
observation and serial ultrasound examination. Minimally
invasive follicular thyroid carcinoma tends to behave like a
follicular adenoma. There is a very low incidence of metas-
tasis in low grade follicular carcinoma [55, 56]a n du n l i k e
papillary thyroid carcinoma, minimally invasive lesions
are rarely multifocal. However, as follicular lesions grow
larger than 3cm, nearly 30% will demonstrate malignant
conversion [57] .W h i l es o m eh a v ea d v o c a t e ds u p p r e s s i v e
therapy for low risk patients, this approach has failed to
demonstrate the beneﬁt of suppressive therapy.
2.2.2. Management of Regional Disease in Well Diﬀerentiated
Thyroid Carcinoma. Unlike squamous cell carcinoma, the
impact of lymph node metastasis from thyroid cancer on
survival is negligible, at least in the younger population.
Several studies have suggested that lymph node metastasis
may not impact survival [58, 59] however when adjusted
for age, it is clear that although regional disease does
not signiﬁcantly impact on survival in young patients,
it does decrease survival in patients over the age of 45
[60]. Long term studies have conﬁrmed these observations
and identiﬁed that in the population of patients over 45
years old, regional metastasis does impact survival [37].
As a result, most experts agree that clinically involved
regional lymph nodes should be managed with a lymph
node dissection. There is, however, controversy regarding
the impact of elective neck dissection on survival. This
is largely a result of the paucity of controlled random-
ized studies. Thyroid cancer commonly progresses in a
deﬁned pathway from the ﬁrst echelon lymph nodes of the
paratracheal region to the lateral compartment (levels III
and IV), however it has been documented that regional
disease may occur in the jugular chain without evidence
of disease in the paratracheal basin in as many as 18%
of cases [59]. In spite of this rather high rate of “skip
metastasis”, most surgeons do not advocate a lateral neck
dissection unless there is clinical evidence of disease in the
lateral compartment. The rate of occult regional metastasis
in papillary thyroid carcinoma is relatively high however
occult metastasis in follicular carcinoma is rare. Hence, in
patients with follicular carcinoma, an elective lymph node
dissection is not commonly performed in the N0 neck. IfJournal of Thyroid Research 5
lymphadenopathy is detected, a paratracheal and pretracheal
central compartment neck dissection should be performed.
In papillary thyroid carcinoma, the high rate of paratracheal
disease constitutes an ipsilateral paratracheal neck dissection
when there is clinical evidence of disease. Node plucking
is not acceptable as the rate likelihood of recurrence is
exceedingly high [61].
2.2.3.ManagementoftheN0Neck. Theapproachtomanage-
ment of the N0 neck in papillary carcinoma has been a topic
of controversy largely because there are few randomized,
controlled, long term studies that demonstrate the impact of
surgical treatment of the N0 neck. Currently, most surgeons
perform a pretracheal and ipsilateral paratracheal lymph
node dissection on high risk patients (those patients aged
45 years or older, or patients with tumors greater than
4cm, or invasive disease). Only when the thyroid tumor
crosses the midline is a contralateral lymph node dissection
warranted. When a contralateral lymph node dissection is
performed, the patient must be informed of the increased
risk related to transient and permanent hypoparathyroidism
[62]. As discussed earlier, in spite of the relatively high
rate of documented skip metastasis, most surgeons do not
advocate a lateral neck dissection. The rationale for this
approach stems from the lack of data demonstrating the
beneﬁt of a lateral neck dissection for subclinical disease
and the prevailing belief that I131 can be used to manage
microscopic lateral metastasis.
2.2.4. Management of N+ Neck. Unlike follicular carcinoma
in which lymph nodes metastases are rare, metastasis in
papillary thyroid carcinoma is common. While only a small
proportion of patients will initially present with a neck mass
[63], a signiﬁcant number of patients will harbor subclinical
paratracheal disease at the time of diagnosis. The size of the
primary thyroid tumor has little bearing on the extent or
location of regional disease. Several groups including our
own, have found that while large cancers of the thyroid
may remain localized, microcarcinoma may present with
extensive regional disease [64]. As a result, it is diﬃcult to
predict the risk of regional disease based on the size of the
tumor and therefore every patient must be evaluated for
regional metastasis.
W h e nl y m p hn o d em e t a s t a s i si si d e n t i ﬁ e d ,an e c k
dissection is warranted. I131 has not been demonstrated
eﬀective for management of gross regional disease [65].
In the past, there was controversy regarding the extent
of the dissection however most surgeons now advocate a
selective neck dissection (levels III, IV, and VI) in which the
jugular vein, sternocleidomastoid muscle, and the accessory
nerve are preserved. Although rare, when invasion of the
surrounding structures occurs, a modiﬁed neck dissection
may be warranted.
2.2.5. Radioiodine Therapy. Remnant ablation with 131I is
routinely performed in all patients except for very low
risk patients after total thyroidectomy to decrease the risk
of recurrence and facilitate monitoring of thyroglobulin.
Usuallythyroidreplacementisdiscontinuedandalowiodine
diet instituted in an eﬀort to increase the avidity of the
residual thyroid tissue. Once the TSH has risen above 25 to
30mU/L, the patient is given radioiodine in doses ranging
30mCi to 100mCi. Patients in whom residual microscopic
disease is suspected and those with more aggressive tumor
histology or known distant metastasis are administered
higher doses of I131 in the range of 100 to 300mCi. Younger
patients with iodine avid tumors tend have a favorable
response to 131I.
Hypothyroidismcanbeavoidedbyadministeringrecom-
binant human TSH (rhTSH, thyrotropin alfa) before admin-
istration of 131-I for remnant ablation [66, 67]. Short-
term results of radioiodine ablation appears to be similar
after rhTSH administration or thyroid hormone withdrawal.
In one study the radiation dose to the thyroid bed of a
tracer amount of radioiodine was similar after two injections
of thyrotropin alfa or thyroid hormone withdrawal [68].
In retrospective studies, the percentage of patients with
successful ablation was similar in patients treated with
r h T S Hc o m p a r e dt ow i t h d r a w a l[ 66, 67]. Pacini et al. [69],
performed an study, with remnant ablation with 30mCi
(1110MBq) after withdrawal of thyroid hormone, and after
rhTSH aloneand after combining withdrawal and rhTSH,
resultedinsuccessfulablationin84%,54%percent,and79%
of patients, respectively. The rate was signiﬁcantly lower in
patients prepared with rhTSH alone. In another trial [70],
remnant ablation with 54mMi (2000MBq) after withdrawal
of thyroid hormone or after rhTSH resulted in similar rates
of successful ablation.
Although one retrospective study [71] found similar
short-term recurrence rates in patients prepared with tradi-
tional thyroid hormone withdrawal, no long-term random-
ized study has been published comparing both approaches.
Because of the lack of long-term data on recurrence and
disease-speciﬁc survival, some centers are oﬀering rhTSH
ablation to only low risk patients preferring traditional
hypothyroid withdrawal for patients at higher risk of recur-
rence or death from disease. This approach follows the
American Thyroid Association guidelines [72].
The response of pulmonary metastasis to I131 is pred-
icated on the size of the lesion, the age of the patient,
and its ability to concentrate I131 [73, 74]. In contrast,
bone metastases, which occur more commonly in follicular
thyroid carcinoma, are less responsive to therapy. The use
of recombinant human TSH (rhTSH) for remnant ablation
and in the treatment of metastatic disease is now being
studied and has the advantage of avoiding symptomatic
hypothyroidism [75].
2.2.6. Thyroid Hormone Suppression. Thyroid hormone sup-
pression is routinely used after total thyroidectomy for dif-
ferentiated thyroid cancer. Although randomized controlled
trials are lacking, beneﬁt was suggested in a large meta-
analysis [76]. Higher risk patients are initially treated with a
greaterdegreeofsuppression.Duetotheriskofosteoporosis,
many clinicians will now reduce the levothyroxine dose once
the patient has been free of disease for several years.6 Journal of Thyroid Research
2.2.7. Role of External Beam Radiotherapy. Although
prospective controlled trials are lacking, several studies
have shown excellent local-regional control of disease with
external beam radiotherapy (EBRT) in patients with locally
advanced diﬀerentiated thyroid cancer after the primary
surgery and before or after radioiodine [77–79]. Several
groups have suggested that EBRT be considered in patients
over 45 years with suspect persistent local disease after
surgery which is unlikely to respond to radioiodine [78, 80].
2.2.8. Diagnosis of Recurrent and Distant Disease. Recurrent
well-diﬀerentiated thyroid cancer is not uncommon. Follow-
ing total thyroidectomy, as many as 15% of patients will
develop neck disease 0 to 5 years after initial therapy [64, 81].
Since the volume of recurrent or distant metastatic disease
correlates relatively well with the prognosis, early diagnosis
and management is essential. Whole body I131 scanning and
should be performed in high risk patients 6 to 12 months
after the primary surgery. Low risk patients can usually
be evaluated by recombinant TSH (Thyrogen) stimulated
thyroglobulin levels avoiding the need for an iodine scan.
Since the majority of recurrences occur in the thyroid
bed, neck ultrasonography represents the most sensitive
means for detecting recurrence in the presence of elevated
thyroglobulin.Forthosepatientswithelevatedthyroglobulin
and a negative iodine scan, PET/CT is exceptionally helpful
in identifying recurrent and distant disease and has been
shown to provide important prognostic information. Jadvar
etal.evaluated10patientswithsuspectedrecurrentpapillary
thyroid cancer using PET and concluded in this small
series that PET was useful in the evaluation of patients
with suspected recurrent papillary thyroid cancer when
the I131 scan is negative [82]. In a more recent study,
eight patients underwent combined PET/CT scanning for
suspected recurrence. Four (50%) of 8 patients underwent
PET/CT indicating recurrence in the head and neck. A total
of 11 lesions in these 4 patients were suspicious for recur-
rence on combined PET/CT imaging. Three patients with
8 lesions suspicious for recurrence on PET/CT underwent
surgical removal of disease. All 3 patients had pathologic
conﬁrmationofrecurrence,with75.0%ofthe8lesionsbeing
positive. The authors concluded that combined PET/CT
imagingisavaluabletoolforthediagnosisandlocalizationof
recurrent thyroid cancer [83]. Recent evidence suggests that
PET-positivediseaseisunlikelytoI131andmaybeassociated
with a more biologically aggressive tumor [84].
2.2.9. Management of Recurrent Disease. The management
of recurrent or metastatic disease largely depends on the
extent of the disease. When there is microscopic persis-
tent or recurrent disease, I131 dosing should be repeated.
However when palpable gross tumor is identiﬁed, surgical
managementisthetreatmentofchoice.Whendistantdisease
is identiﬁed, adjuvant I131 is usually the preferred. I131
scanning is the most accurate method for assessment of
distant disease [85]. Noniodine avid tumors represent a
challengeandmayindicateapoorlydiﬀerentiatedtumorthat
is often associated with a more aggressive behavior and a
poor prognosis [84]. EBRT may be used for gross residual
disease unresponsive to radioiodine and not amenable to
furthersurgery.Externalbeamradiationorsurgicalresection
can also be used for the management of pain or to
decompressnerverootcompressioninthevertebraehowever
neither therapy has an impact on prognosis. There are few
studies demonstrating the eﬃcacy of systemic chemotherapy
however there is data to suggest that doxorubicin may be
eﬀective in some patients (60–75mg/m2 every 3 weeks) [86].
Currently, systemic chemotherapy is used only in clinical
trials.
2.3. Hürthle Cell Carcinoma. Hürthle cell carcinoma (HCC)
is a relatively rare form of thyroid cancer that is generally
considered to be a more aggressive variant of follicular
carcinoma. Similar to follicular carcinoma, the distinction
between a benign Hürthle cell adenoma and a HCC is
determined on the presence of vascular or capsular invasion.
Similar to follicular cell carcinoma, the diagnosis cannot be
made on ﬁne needle aspiration or frozen section analysis.
Patients with HCC tend to be older. In one review series, it
was found that the median age of presentation for patients
with follicular cell carcinoma was 55 years while the HCC
patients presented at a mean age of 62 years. Patients
presenting with HCC have a lower risk of regional metastasis
at presentation when compared with follicular carcinoma,
but a slightly increased risk of distant metastasis [63]. When
followed long term, the number of patients that eventually
develop distant metastasis is higher in HCC patients (30%)
thanpapillaryorfollicularthyroidcarcinomapatients.When
distantmetastasisoccurs,40%occurintheboneandasmany
as 30% occur in the lung [87].
2.3.1. Management of Hürthle Cell Carcinoma. The manage-
ment of HCC is not signiﬁcantly diﬀerent from follicular cell
carcinoma. HCC with minimal capsular invasion (<1mm)
can be safely managed with a thyroid lobectomy and isth-
musectomy. However, because it has been demonstrated that
patients treated with a total thyroidectomy have a lower risk
of recurrence [84, 88], recommend a total thyroidectomy.
All high risk patients or patients with more extensive
capsular invasion are managed with a total thyroidectomy.
Following surgery, I131 is administered to achieve ablation
and facilitate surveillance with thyroglobulin.
2.3.2. Prognosis of Hürthle Cell Carcinoma. Less that 200
new cases of HCC carcinoma are diagnosed in the United
States each year. As a result, there are few long term outcome
studies however, Evans and Vassilopoulou-Sellin found in
1998 no diﬀerence in outcome between HCC and follicular
cell carcinoma when cases are stratiﬁed by extent of invasion
[89]. Like follicular cell carcinoma, the most important
factor in assessing the prognosis seems to be the extent of
capsularinvasion.Whentumorsinvadelessthan1.0mm,the
rate of recurrence in exceedingly small, however as the extent
of capsular invasion increases, the likelihood of regional and
distant metastasis increases [89].Journal of Thyroid Research 7
Table 5: Familial medullary thyroid carcinoma.
Familial Medullary Thyroid Cancer
MEN IIA
Medullary thyroid cancer
Parathyroid adenoma
Pheochromocytoma
MEN IIB
Medullary thyroid carcinoma
Pheochromocytoma
Ganglioneuromatosis
Marfanoid habitus
2.4. Medullary Thyroid Carcinoma. Medullary thyroid carci-
noma (MTC) is derived from the nonepithelial parafollicular
cells (c-cells) which produce the peptide calcitonin. Since the
parafollicular cells embryo logically develop from the neural
crest or diﬀuse neuroendocrine system, they commonly
produce neuropeptides and catecholamines. Tumors deriv-
ing from diﬀuse neuroendocrine system, such as carcinoid
tumors, pancreatic islet tumors, and pheochromocytomas,
are cytologically and functionally similar. MTC exists in a
sporadic and familial forms. While the gender distribution
is roughly equivalent, the sporadic form of the disease occurs
in 80 to 90% of newly diagnosed cases. The familial form of
the disease occurs in an autosomal dominant trait as either
isolatedfamilialmedullarythyroidcarcinoma(FMTC),mul-
tiple endocrine neoplasia type IIA (MEN IIA), or multiple
endocrine neoplasia type IIB (MEN IIB) (Table 5). Each
of these familial forms of the disease is associated with a
ret oncogene mutation located on chromosome 10. This
provides a reliable screening tool to identify aﬀected family
members. Since the penetrance of medullary thyroid cancer
is >90% in people with the RET gene mutation, prophylactic
thyroidectomy is recommended at a young age [90].
2.4.1. Clinical Presentation of MTC. Not unlike other forms
of thyroid carcinoma, sporadic MTC typically presents as
a thyroid nodule with or without an associated neck mass.
Since MTC is derived from the diﬀuse neuroendocrine
system,patientsmaypresentwithaparaneoplasticsyndrome
resulting in diarrhea and abdominal cramping as a result of
prostaglandin and vasoactive peptide release. The biological
behavior and clinical presentation of MTC can be variable.
Most tumors present as a well circumscribed encapsulated
nodule within the thyroid gland. More aggressive tumors
may present with a neck mass or in rare cases distant
metastasis to the lungs, liver, or adrenal glands. In some
cases, tumors may remain stable or quiescent while other
tumors may progress rapidly. There has been little data to
help predict the biological aggressiveness of MTC.
2.4.2. Diagnosis of MTC. The most accurate method for
diagnosis of MTC is an FNA of the thyroid nodule or
neck mass. While cytodiagnostic features are recognized
[91], immunostaining for calcitonin in the presence of
negative thyroglobulin staining, is the most accurate method
of diagnosis. When the calcitonin polymerizes, amyloid
deposits can be found on histological analysis. There are
no histological diﬀerences between the sporadic and familial
forms of the disease. However, it is interesting to note that
familial MTC has a predilection for presenting as a thyroid
nodule at the junction of the upper third and lower two-
thirdsofthethyroidglandbecausethisistheareaofthegland
in which the density of C cells is the highest. Sporadic disease
usually presents as a unilateral nodule while familial disease
is more commonly bilateral and multifocal. Familial disease
is considered more aggressive and commonly presents in the
second or third decades while sporadic disease presents later,
in the sixth or seventh decades.
Newly diagnosed patients with MTC should be staged both
biochemically and radiologically.M e a s u r e m e n t so fs e r u mcal-
citonin and carcinoembryonic antigen (CEA), to determine
whether they are produced by the tumor and, if so, as a
baseline for comparison with results obtained before and
after surgery. Patients with higher preoperative serum calci-
tonin concentrations have larger tumors and are less likely to
achieve normal concentrations after [92]. Patients who have
normal serum CEA and serum calcitonin, are considered
biochemically cured and have the best prognosiswith a ﬁve
recurrence rate of only 5% [93].
The serum calcitonin concentration falls slowly in some
patients, with the nadir not being reached for several months
[94].A high basalserumcalcitonin valuesix or more months
after surgery is presumptive evidence of residual disease.
Subsequent follow-up should include periodic physical
examination and measurements of serum calcitonin and
CEA.
2.4.3. Management of MTC. Medullary thyroid carcinoma
requires a total thyroidectomy and paratracheal lymph node
dissection. Larger thyroid tumors are associated with an
increased risk of neck disease and therefore tumors greater
than 2cm should be treated with an ipsilateral selective neck
dissection in addition to a bilateral paratracheal lymph node
dissection [95]. Some have suggested that all patients should
be treated with bilateral selective neck dissections because
patients with unilateral intrathyroidal tumors, as many as
81% of patients have lymph node metastasis in levels II–
V and 44% have disease in the contralateral lymph nodes
level II–V [96]. Aggressive surgical therapy is warranted
because occult metastases are common and surgery is the
only eﬀective method of therapy. There is no evidence that
medical therapy has any role in the primary management
of MTC and there is little evidence to suggest that adjuvant
medical therapy will impact outcome. There is no role
for radioiodine or thyroid hormone suppression in the
treatment of medullary cancer. Brierley et al. treated a series
of 40 patients at high risk for recurrence with external
beam radiation and demonstrated an improvement in local-
regional control (86% versus 52%) at 10 years [80, 97]
however several other studies have failed to demonstrate an
improvement in survival with external beam radiotherapy
[98, 99]. Systemic chemotherapy has little impact on the
natural course of the disease, and while Schlumberger et al.8 Journal of Thyroid Research
demonstrated 20% response rate in patients treated with
doxorubicin, there is little data to support the use of systemic
chemotherapy in MTC [100]. A new therapy using pretar-
geted anticarcinoembryonic antigen radioimmune therapy
(RIT) has shown a survival beneﬁt in a small clinical trial
[101].
2.4.4. Management of Regional Disease. When faced with
regional recurrence, surgery is the treatment of choice.
Regional metastasis mandates a neck dissection. Unlike well-
diﬀerentiated thyroid cancer.
Radioactive iodine uptake is negligible in MTC and
therefore aggressive surgical management of regional disease
is justiﬁed. If a bilateral neck dissection was not performed at
the time of initial therapy, bilateral neck dissections should
be considered, even in the face of unilateral recurrence.
2.4.5. Management of Distant Disease. Distant disease rep-
resents a signiﬁcant dilemma. As discussed, conventional
adjuvant therapy oﬀers little for patients with regional or
distant disease. Clinical trials are often oﬀered at tertiary care
medical centers.
2.4.6.ManagementofRecurrentandPersistentDisease. When
patients demonstrate a persistently elevated calcitonin level
following surgery, it is because there is residual or recurrent
disease. Identifying the location of the residual disease is
often a challenge. CT, MRI, and PET have all been used
with little success unless there is gross disease remaining in
the neck or thyroid bed. The management of a patient with
a persistently elevated calcitonin level and no radiographic
evidence of disease is controversial. This is because there
is evidence to suggest that this patient group does not
necessarily have a compromised outcome [102]a n dw h e n
reoperation is pursued, the rate of success is low [103].
We recommend bilateral selective neck dissections for those
patients that have not already undergone a neck dissection.
2.4.7. Prognosis of MTC. Prognosis is better in younger
patients, female gender, familial disease, and those with
disease conﬁned to the thyroid gland. The overall 5-year
survival rate ranges from 25% to 75% [104, 105]. When
nodaldiseaseispresentatthetimeofdiagnosis,whichoccurs
in 50% of patients, the 5-year survival rate drops to less than
50% [106]. A recent series suggests that the 5 and 10 year
survival rates are as high as 90% and 80% [107].
2.5. Anaplastic Thyroid Carcinoma. Although less than 2%
of all thyroid carcinomas are anaplastic thyroid carcinoma
(ATC), it accounts for 14–39% of thyroid carcinoma deaths
[108].
Anaplastic Thyroid Cancers are the most aggressive of
the thyroid cancers. Mutations of the p53 tumor suppressor
gene that lead to production of an inactive p53 protein
occur in most anaplastic thyroid cancers, and not in other
thyroid [109]. Mutations of the beta-catenin gene occur in
up to 65 percent of anaplastic thyroid carcinomas [110].
It has been suggested that diﬀerentiated thyroid cancers
may deteriorate into anaplastic thyroid cancers, it has been
proposed that several diﬀerent gene mutations provide an
early growth advantage and that p53 mutations are the ﬁnal
step in the development of an anaplastic cancer. Evidence
comes from studies describing well diﬀerentiated regions
inside anaplastic cancers and the consequent mutation of
BRAF, acquiring p53 mutation in a second step [111, 112].
However, in one study of 17 anaplastic cancers, no RET gene
rearrangements were detected, providing no evidence for the
evolution of papillary into anaplastic thyroid cancer [113].
Somatic mutations of the catalytic subunit of the phos-
phatidylinositol 3 -kinase (PIK3CA) have been identiﬁed in
about 23 percent of anaplastic thyroid cancers [114]. In
anaplastic thyroid cancers with well diﬀerentiated compo-
nents, the PIK3CA mutations are restricted to the anaplastic
component.
The diagnosis of anaplastic thyroid carcinoma can be
elusive. Not uncommonly, an FNA will be repeatedly inter-
preted as “undiﬀerentiated carcinoma” until an open biopsy
provides enough tissue to reveal the anaplastic nature of the
carcinoma. Unlike other forms of thyroid cancer, anaplastic
is characteristically aggressive and unrelenting. Accounting
for less than 5% of malignant thyroid cancers, anaplastic
thyroid cancer is often heralded by a rapidly growing thyroid
mass with destruction of the adjacent cartilage, nerve and
inﬁltrating muscles.
The group of Chan et al. [115] in Hong Kong recently
analyzed the clinico-pathological features, treatment and
outcome of all patients with ATC treated over the past
four decades in their institution. Fifty patients presenting
with biopsy-proven ATC between 1966 and 2006 were
studied. All patients were managed with surgery, radiother-
apy, chemotherapy, or chemoradiation. Distant metastases
at diagnosis were present in nine patients. The results
conﬁrmedthedismaloutlooknotedinpreviousstudies,with
amediansurvivalofonly97days,with1-and3-yearsurvival
of 14% and 8% respectively. Age 65 years or younger, lack
of metastatic disease, surgical resection, and radiation to the
neck were associated with better prognosis on univariate
analysis. Cytotoxic chemotherapy was not associated with
improvedsurvivalanddisappointingly,nochangeinsurvival
was seen over the 40-year period of the study. This and other
studies emphasize the need for new treatment strategies for
ATC [115–117].
2.5.1. Clinical Presentation of ATC. Anaplastic thyroid car-
cinoma typically presents in the elderly population with
a history of thyroid goiter [118]. Up to 20% of patients
will have a history of well-diﬀerentiated thyroid cancer or
co-existing well-diﬀerentiated thyroid cancer present within
the thyroid specimen [119, 120]. Patients usually present
with a rapidly growing neck mass, true vocal cord paralysis,
and or dysphagia [118] .T h em a s st e n d st op r e s e n ta sa
ﬁxed neck mass invading the surrounding structures. Direct
invasion of the airway and larynx can lead to hoarseness or
airway obstruction. As the lesion becomes more advanced,
esophageal invasion can result in dysphagia. Anaplastic
carcinoma may arise de novo or as a “conversion tumor”Journal of Thyroid Research 9
arising in the presence of a preexisting papillary or follicular
carcinoma. When anaplastic carcinoma arises de novo, the
tumor may progress rapidly metastasizing to the lungs, liver,
and bones within weeks of presentation.
2.5.2. Diagnosis of ATC. A FNA is often the ﬁrst approach to
diagnosis however necrosis and degeneration of the tumor
may occur as the tumor rapidly out grows its blood supply.
A FNA aspiration may yield necrotic material. Alternatively,
the FNA may yield poorly diﬀerentiated cells suggestive
of either lymphoma, anaplastic thyroid cancer, or poorly
diﬀerentiatedcarcinomaofunknownorigin.Flowcytometry
isusefultoruleoutlymphoma,howeverimmunohistochem-
istry and electron microscopy may be necessary to conﬁrm
the diagnosis of anaplastic thyroid carcinoma.
2.5.3. Management of ATC. There is controversy regard-
ing the ideal management of anaplastic carcinoma largely
because it is rapidly progressing and poorly responsive to
therapy [121]. Deﬁning the goals of management is essential.
The options for therapy range from multimodal therapy,
surgical resection, debulking, radiotherapy, chemotherapy,
and palliative therapy [118, 122, 123]. Early disease, disease
conﬁned to the thyroid gland, is poorly responsive to
unimodality therapy, however in a recent study, investigators
reviewed a cohort of 516 patients with anaplastic thyroid
carcinoma reported to 12 population based cancer registries
between 1973 and 2000. They found that patients less than
60 years old with intrathyroidal anaplastic thyroid cancer
appear to have a better prognosis than older patients with
extra-thyroidal spread following total thyroidectomy and
external beam radiation [124]. Long term survivors are few
however in those that do survive the disease, they commonly
have only a small focus of anaplastic tumor arising within
a preexisting well-diﬀerentiated thyroid cancer [17, 125].
Adjuvant therapy has also been controversial. Standard
fractionated radiation therapy has not been demonstrated
to signiﬁcantly change the clinical course [126]. Hyperfrac-
tionated therapy has resulted in a marginal improvement in
responserateshoweverthesideeﬀects,includingesophagitis,
can be debilitating [127]. Tennvall et al. reported using pre-
operative hyper fractionated radiation (30Gy), doxyrubicin,
and surgical resection followed by postoperative radiation
(46Gy). They demonstrated promising results with this
regimen, controlling local recurrence in 48% of patients and
disease free survival in 12% [128]. In advanced disease, the
goals include establishing an airway, a source of nutrition,
and an acceptable quality of life. Surgery is warranted for the
control or prevention of airway obstruction or extensive skin
ulceration.
2.5.4. Prognosis of ATC. Anaplastic thyroid carcinoma is one
of the most aggressive human malignancies. It is associated
with an almost uniformly rapid and lethal clinical course
[129]. Several studies have conﬁrmed the universal lethal
course associated with anaplastic thyroid cancer. Patient age,
gender, tumor size, extent of disease, leukocytosis, presence
of acute local symptoms, coexisting multinodular goiter and
well diﬀerentiated thyroid carcinoma, surgical resection, and
multimodal therapy all reportedly inﬂuence patient survival
according to some studies [130, 131]. However, there are few
interventions that have improved survival.
3. The New Insights
3.1. New Agents in the Treatment of Diﬀerentiated Thyroid
Cell Carcinoma. Axitinib (AG-013736) is a potent small
molecule inhibitor of VEGF receptors 1, 2, and 3. A single
arm multicenter study evaluated the eﬃcacy of this novel
compound in advanced thyroid cancers. Sixty patients with
metastatic or unresectable locally advanced thyroid cancer
refractory to or not suitable candidates for radioiodine
treatment, received axitinib at a starting dose of 5mg orally
twice daily. The majority of the patients had diﬀerentiated
thyroid cancer and two had anaplastic cancer. There were
18 partial responses and 30 patients had stable disease. The
median progression free survival had not been reached at a
median follow up of 273 days. Therapy was well tolerated
with fatigue being the main side eﬀect. Importantly the
study was a proof of principle as levels of soluble VEGF
receptor were consistently decreased and levels of VEGF in
the blood were increased demonstrating pharmacodynamic
activity against targeted VEGF receptors [132, 133].
Sorafenib, a multitargeted small molecule kinase
inhibitor, including the VEGF receptor and BRAF kinase,
has also been evaluated in patients with thyroid cancer.
Of 19 evaluable patients with metastatic, iodine refractory,
papillary thyroid cancer enrolled in a phase II trial of
sorafenib, ﬁve patients achieved a partial response and
eight had stable disease with sorafenib. Median response
duration was 14.2 months (12–15þ months) and median
time to progression of all patients was 4þ months (4
days to 14.5þ months). Pharmacodymanic analysis of
tumor tissue before and after sorafenib treatment (at 1
and 2 weeks) in two patients revealed reduction in pERK
(downstreamofVEGFRandBRAF)andpAKT(downstream
of VEGFR) [134]. Sorafenib is currently US Food and Drug
Administration approved for the treatment of renal cell
cancer and hepatocellular carcinoma. It has side eﬀects
including a desquamating rash often on the hands and can
cause gastrointestinal symptoms. It is currently being used
in many trials across the world and in many malignancies
and its role in the treatment of thyroid cancer is likely to
increase.
In the Phase II trial of Gupta-Abramson et al. [135],
thirty patients were treated for a minimum of 16 weeks
with Sorafenib 400mg twice daily. Seven patients had a
partial response lasting from 18 to 84 weeks. Sixteen patients
had stable disease lasting from 14 to 89 weeks. Seventeen
(95%) of 19 patients for whom serial thyroglobulin levels
were available showed a marked and rapid response in
thyroglobulin levels with a mean decrease of 70%. The
median PFS was 79 weeks. Toxicity was consistent with other
sorafenib trials, although a single patient died of liver failure
that was likely treatment related.10 Journal of Thyroid Research
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Figure 1: RET mutations in medullary thyroid carcinoma.
The overall clinical beneﬁt rate (partial response stable
disease) in this study was of of 77%, median PFS of 79 weeks,
and an overall acceptable safety proﬁle.
AMG-706 Finally, in a third abstract reported at the 2007
annual meeting of the American Society of Clinical Oncol-
ogy, AMG-706, another multikinase inhibitor (VEGF/PDGF
receptors, Kit and RET), was studied in a phase II trial
of patients with advanced diﬀerentiated thyroid cancer or
medullary thyroid cancer. All subjects received AMG 706
daily until disease progression or unacceptable toxicity. The
results for the diﬀerentiated group with median follow up
of 32 weeks were presented at the meeting. Twelve percent
of patients had a partial response and another 69% had
stable disease. Side eﬀects were tolerable with diarrhea and
hypertension being the most common severe toxicities (11
and 22%, resp.) [136]. These three studies show the renewed
interest in refractory thyroid cancer management and that
small molecule inhibitors oﬀer one of the most exciting
prospects for the treatment of these patients.
Cyclo-oxygenase 2 (COX-2) is an enzyme overexpressed
in many thyroid cancers. Inhibition of this enzyme has
been shown to reduce progression of tumors in animal
models and humans. Two common oncogenes in papillary
thyroid cancer, RET/PTC1 and RET/PTC 2, induce expres-
sion of COX2. Celecoxib, a widely available selective COX-
2 inhibitor, seemed therefore to be an attractive potential
treatment for this disease. Unfortunately an early study using
this drug failed to show a beneﬁt at a dose of 400mg twice
daily [137].
Geﬁtinib (Iressa) is a tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR). This receptor is
highly expressed on normal and malignant thyroid tissue,
and has been associated with a worse prognosis in well
diﬀerentiated thyroid cancer. Preclinical studies have estab-
lished in-vitro activity of geﬁtinib against thyroid cancer.
Although a phase II clinical trial with geﬁtinib reported
no objective responses by RECIST criteria in 27 patients
withradioiodineresistantthyroidcancer,reductionintumor
volumewasnotedin32%ofthepatients,and12%ofpatients
had no evidence of progression after one year of treatment.
Thyroglobulin levels were decreased to 90% of baseline in
ﬁve patients with stable disease. Overall survival was 17.5
months in the cohort [138, 139].
3.2. New Agents in ATC. Some of the multikinase inhibitors
mentioned above have shown hints of activity in the few
patients enrolled with ATC. Another antiangiogenesis com-
pound,combrestatinA4phosphate(CA4P),hasfurtherbeen
evaluated in a cohort of patients with ATC. Unlike the other
angiogenesis inhibitors such as bevacizumab, an antibody
against VEGF, or the VEGF receptor kinase inhibitors, CA4P
is a tubulin-binding vascular disrupting agent that stops
blood ﬂow through existing blood vessels, depriving the
tumor of its nutrients and oxygen. A phase II study with
this agent in 18 patients with ATC was reported last year.
Although there were no objective responses, six patients had
stable disease and 28% had no progression of disease forJournal of Thyroid Research 11
greater than 3 months [28, 140]. Based on these results, an
international phase III study has been planned evaluating
the use of CA4P in combination with the widely used
chemotherapy pair of paclitaxel and carboplatin. Patients
with unresectable ATC will be randomized to chemotherapy
with or without CA4P. The study is a huge undertaking
given the rare and aggressive nature of the disease, and oﬀers
some hope to a population of patients with no other eﬀective
treatments.
3.3. New Agents in MTC. One of the hallmarks of MTC
is the association with the rearranged during transfection
protooncogene (RET) (Figure 1). In normal states, this gene
is involved in cell signaling, and regulates the production
of proteins that are essential for spermatogenesis and the
development of the autonomic nervous system and kidneys.
RET is a transmembrane protein that can be activated
by extracellular signals and initiate a complex cascade of
intracellular reactions regulating cell growth. A tyrosine
kinase enzyme located on the intracellular domain of RET
activates this cell signaling cascade. Mutations in speciﬁc
regions of the RET gene have been described in MTC, and
these occur in both the sporadic and familial form of the
disease [141, 142]. These mutations have led to fascinating
experimentslookingatcorrectivegenetherapyasatreatment
strategy. ZD6474 (Zactima, vandetanib) is a novel anili-
noquinazoline compound with a molecular weight of 475
Daltons. It was considered worthy of further development
after demonstrating potent inhibition of VEGFR-2 tyrosine
kinase in recombinant enzyme assays as well as additional
activity against VEGFR-3, EGFR and RET tyrosine kinases.
Vandetanib showed excellent selectivity for these kinases
compared with related receptor tyrosine kinases such as
platelet-derived growth factor receptor (PDGFR)-b and c-
Kit [143–145]. Its activity in hereditary MTC has been
established in a single arm phase II study, which reported a
17% conﬁrmed and 7% unconﬁrmed partial response rate
in 30 patients, with a 50% stable disease rate. In 23 patients
there was a decrease in calcitonin levels by at least 50%
which was maintained for 4 weeks or longer. Toxicities were
manageable, with the most common adverse events being
diarrhea, rash and asymptomatic QTc prolongation. The
encouraging results of this trial have spurred accrual onto an
ongoing international randomized phase II trial comparing
ZD6474 to placebo [146]. Once the results from this trial
are available, the authors feel that there will probably be
enoughevidencefortheapprovalofZD6474inthetreatment
of metastatic or unresectable MTC, a true landmark in this
disease.
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